Alere (ALRPRB.PFD) EBIT per Share : $0.00 (TTM As of Jun. 2017)

View and export this data going back to 2008. Start your Free Trial

What is Alere EBIT per Share?

Alere's EBIT per Share for the three months ended in Jun. 2017 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2017 was $0.00.

During the past 12 months, the average EBIT per Share Growth Rate of Alere was -216.20% per year. During the past 3 years, the average EBIT per Share Growth Rate was -54.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Alere's EBIT per Share or its related term are showing as below:

ALRPRB.PFD' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 0 Med: -131.6 Max: 112
Current: -54.4

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Alere was 112.00% per year. The lowest was 0.00% per year. And the median was -131.60% per year.

ALRPRB.PFD's 3-Year EBIT Growth Rate is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: -1.95 vs ALRPRB.PFD: -54.40

Alere's EBIT for the three months ended in Jun. 2017 was $-30.53 Mil.

Alere EBIT per Share Historical Data

The historical data trend for Alere's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alere EBIT per Share Chart

Alere Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

EBIT per Share

Get a 7-Day Free Trial

Alere Quarterly Data
	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17
EBIT per Share	Get a 7-Day Free Trial															-	-	-	-	-

Alere EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Alere's EBIT per Share for the fiscal year that ended in Dec. 2016 is calculated as

	EBIT per Share		(A: Dec. 2016 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	19.253	/	0
=	N/A

Alere's EBIT per Share for the quarter that ended in Jun. 2017 is calculated as

	EBIT per Share		(Q: Jun. 2017 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-30.53	/	0
=	N/A

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

Alere (NYSE:ALRPRB.PFD) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Alere EBIT per Share Related Terms

Thank you for viewing the detailed overview of Alere's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Alere (ALRPRB.PFD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Alere Inc (NYSE:ALRPRB.PFD) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.alere.com

Alere, Inc. develops rapid point-of-care diagnostic devices in cardiology, infectious disease, toxicology, diabetes, oncology, and women's health. North America accounts for the largest portion of the firm's revenue (55%), followed by Europe (19%), Asia-Pacific (14%), and the rest of the world (12%). Alere's headquarters are in Waltham, Massachusetts.

Executives

John Bridgen	officer: Sr VP, Business Development	51 SAWYER ROAD, C/O INVERNESS MEDICAL INNOVATIONS INC, WALTHAM MA 02453
Geoffrey S Ginsburg	director	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Renuka Uppaluri	officer: Senior VP, Global R&D	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mark Gladwell	officer: Senior VP, Global Operations	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Gregg J Powers	director	C/O QUANTUM CORPORATION, 224 AIRPORT PARKWAY SUITE 300, SAN JOSE CA 95110
Jonathan Wygant	officer: VP, Controller, CAO	3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Thomas Mckillop	director	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Melissa Guerdan	officer: SVP, Global Quality & Reg.	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Daniella Cramp	officer: Global Pres., Cardiometabolic	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Sanjay Malkani	officer: Global Pres., Toxicology	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
James Jr. Roosevelt	director	51 SAWYER ROAD, SUITE 200, HOPKINTON MA 02453
Robert Bernard Hargadon	officer: SVP, Global Human Resources	4327 LAKE WASHINGTON BLVD NE #6208, KIRKLAND WA 98033
John F Levy	director	C/O INNVERNESS MEDICAL INNOVATIONS, INC., 51 SAWYER ROAD, WALTHAM MA 02453
John Quelch	director	C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYER RD, WALTHAM MA 02453
Carol R Goldberg	director	C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYERS RD, WALTHAM MA 02453